Metoclopramide Hydrochloride | US Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Metoclopramide Hydrochloride
US Patents

PharmaCompass Sponsored Ads

Contact Supplier

Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

Contact Supplier

xyz-pharma-m-2025-03-24

Contact Supplier

LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

Contact Supplier

Gentec Pharmaceutical Group is focused on manufacturing & developing APIs/HPAPIs, Advanced Intermediates & Fine Chemicals.

Contact Supplier

xyz-pharma-m-2025-03-17

Contact Supplier

Metoclopramide Hydrochloride

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

22 API Suppliers, 10 USDMF, 4 CEP/COS, 1 JDMF, 3 EU WC, 9 NDC API, 16 Listed Suppliers, $ API Reference Price

22 API Suppliers
10 USDMF
4 CEP/COS
1 JDMF
3 EU WC
9 NDC API
16 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

3 Drugs in Development

3 Drugs in Development

INTERMEDIATES

2 Intermediate Suppliers

2 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

116 FDF Dossiers, 78 FDA Orange Book, 8 Europe, 8 Canada, 4 South Africa, 18 Listed Dossiers

116 FDF Dossiers
78 FDA Orange Book
8 Europe
8 Canada
4 South Africa
18 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INJECTION - EQ 5MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, ORALLY DISINTEGRATING;ORAL - EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, ORALLY DISINTEGRATING;ORAL - EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - EQ 5MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET, ORALLY DISINTEGRATING;ORAL - EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET, ORALLY DISINTEGRATING;ORAL - EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 5 Evonik, 5 Rochem International Inc, 18 SPI Pharma, 6 DKSH, 5 Faran Shimi Pharmaceutical, 5 Boai NKY Pharmaceuticals Ltd, 7 Gangwal Healthcare, 3 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 4 ACG Worldwide, 6 Actylis, 1 Alcedo Pharmachem, 6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 17 BASF, 2 Corel Pharma Chem, 6 DFE Pharma, 1 Finar, 7 Gangwal Chemicals, 1 Ideal Cures Pvt Ltd, 4 Ingredion Pharma Solutions, 27 Kerry, 3 Lonza Capsugel, 16 Microlex e.U, 2 Novo Excipients, 4 Pharmatrans-Sanaq, 6 Pluviaendo, 3 Prachin Chemical, 1 Qualicaps, 28 Roquette, 1 Seppic, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 2 Shijiazhuang Huaxu Pharmaceutical, 10 Sigachi Industries, 1 Ulanqab Kema New Material, 2 Valens Pharmachem, 3 Vasa Pharmachem, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

86 Fillers, Diluents & Binders, 36 Direct Compression, 33 Disintegrants & Superdisintegrants, 29 Taste Masking, 23 Granulation, 22 Thickeners and Stabilizers, 19 Chewable & Orodispersible Aids, 19 Film Formers & Plasticizers, 17 Parenteral, 15 Co-Processed Excipients, 14 Lubricants & Glidants, 13 Coating Systems & Additives, 11 Solubilizers, 9 Controlled & Modified Release, 8 Empty Capsules, 6 Topical, 4 Emulsifying Agents, 1 Soft Gelatin, 1 Rheology Modifiers, 1 API Stability Enhancers

86 Fillers, Diluents & Binders
36 Direct Compression
33 Disintegrants & Superdisintegrants
29 Taste Masking
23 Granulation
22 Thickeners and Stabilizers
19 Chewable & Orodispersible Aids
19 Film Formers & Plasticizers
17 Parenteral
15 Co-Processed Excipients
14 Lubricants & Glidants
13 Coating Systems & Additives
11 Solubilizers
9 Controlled & Modified Release
8 Empty Capsules
6 Topical
4 Emulsifying Agents
1 Soft Gelatin
1 Rheology Modifiers
1 API Stability Enhancers

DIGITAL CONTENT

2 News #PharmaBuzz

2 News #PharmaBuzz

GLOBAL SALES INFORMATION

8 Regulatory FDF Prices

8 Regulatory FDF Prices

MARKET PLACE

10 APIs, 1 FDF Dossiers

10 APIs
1 FDF Dossiers

PATENTS & EXCLUSIVITIES

6 US Patents

6 US Patents

REF. STANDARDS & IMPURITIES

1 EDQM, 1 USP, 1 Others

1 EDQM
1 USP
1 Others

$ API Ref.Price (USD/KG) : 113 Xls

Filters

Reset all filters

Filters

FILTER :

filter Applicant Reset all filters

6 All

01 6EVOKE PHARMA INC

filter Patent Number Reset all filters

6 All

01 18334281

02 111020361

03 111628150

04 111813231

05 112194008

06 112194009

filter API Patent Reset all filters

6 All

01 6Blank

filter FDF Patent Reset all filters

6 All

01 3Y

02 3Blank

filter Expiration Date Reset all filters

6 All

01 52029-12-22

02 12030-05-16

Metoclopramide Hydrochloride

Product Main Page

01

EVOKE PHARMA INC

METOCLOPRAMIDE HYDROCHLORIDE

Immuno-Oncology 360

Not Confirmed

EVOKE PHARMA INC

Immuno-Oncology 360

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2029-12-22

METOCLOPRAMIDE HYDROCHLORIDE

US Patent Number : 11020361

Drug Substance Claim :

Drug Product Claim :

Application Number : 209388

Patent Use Code : U-2843

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2029-12-22

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

EVOKE PHARMA INC

METOCLOPRAMIDE HYDROCHLORIDE

Immuno-Oncology 360

Not Confirmed

EVOKE PHARMA INC

Immuno-Oncology 360

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2029-12-22

METOCLOPRAMIDE HYDROCHLORIDE

US Patent Number : 12194009

Drug Substance Claim :

Drug Product Claim :

Application Number : 209388

Patent Use Code : U-2843

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2029-12-22

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

EVOKE PHARMA INC

METOCLOPRAMIDE HYDROCHLORIDE

Immuno-Oncology 360

Not Confirmed

EVOKE PHARMA INC

Immuno-Oncology 360

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2029-12-22

METOCLOPRAMIDE HYDROCHLORIDE

US Patent Number : 12194008

Drug Substance Claim :

Drug Product Claim :

Application Number : 209388

Patent Use Code : U-2843

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2029-12-22

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

04

EVOKE PHARMA INC

METOCLOPRAMIDE HYDROCHLORIDE

Immuno-Oncology 360

Not Confirmed

EVOKE PHARMA INC

Immuno-Oncology 360

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2030-05-16

METOCLOPRAMIDE HYDROCHLORIDE

US Patent Number : 8334281

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 209388

Patent Use Code : U-2843

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2030-05-16

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

05

EVOKE PHARMA INC

METOCLOPRAMIDE HYDROCHLORIDE

Immuno-Oncology 360

Not Confirmed

EVOKE PHARMA INC

Immuno-Oncology 360

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2029-12-22

METOCLOPRAMIDE HYDROCHLORIDE

US Patent Number : 11628150

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 209388

Patent Use Code : U-2843

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2029-12-22

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

06

EVOKE PHARMA INC

METOCLOPRAMIDE HYDROCHLORIDE

Immuno-Oncology 360

Not Confirmed

EVOKE PHARMA INC

Immuno-Oncology 360

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2029-12-22

METOCLOPRAMIDE HYDROCHLORIDE

US Patent Number : 11813231

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 209388

Patent Use Code : U-2843

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2029-12-22

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!